(Q39078274)

English

Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways

scientific article published on 11 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways (English)

1 reference

Europe PubMed Central

8 September 2017

author name string

Seon Min Woo

1

1 reference

Europe PubMed Central

8 September 2017

Kyoung-Jin Min

2

1 reference

Europe PubMed Central

8 September 2017

In Gyeong Chae

3

1 reference

Europe PubMed Central

8 September 2017

Kyung-Soo Chun

4

1 reference

Europe PubMed Central

8 September 2017

Taeg Kyu Kwon

5

1 reference

Europe PubMed Central

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 October 2013

1 reference

Europe PubMed Central

8 September 2017

Molecular Carcinogenesis

1 reference

Europe PubMed Central

8 September 2017

54

1 reference

Europe PubMed Central

8 September 2017

3

1 reference

Europe PubMed Central

8 September 2017

216-228

1 reference

Europe PubMed Central

8 September 2017

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

EP2 and EP4 prostanoid receptor signaling

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Role of beta-arrestin 1 in the metastatic progression of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostaglandin E2 increases growth and motility of colorectal carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Not so strange bedfellows: G-protein-coupled receptors and Src family kinases

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Chemopreventive efficacy of silymarin in skin and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Multitargeted therapy of cancer by silymarin

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E2 in mouse skin.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Silymarin: a review of its clinical properties in the management of hepatic disorders

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Effect of silibinin on the growth and progression of primary lung tumors in mice.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

The role of COX-2 in breast and cervical cancer.

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Silymarin and epithelial cancer chemoprevention: how close we are to bedside?

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Retracted: Green Tea Catechins Reduce Invasive Potential of Human Melanoma Cells by Targeting COX-2, PGE2 Receptors and Epithelial-to-Mesenchymal Transition

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

The role of the EP receptors for prostaglandin E2 in skin and skin cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.22092

21 January 2018

Identifiers

10.1002/MC.22092

1 reference

Europe PubMed Central

8 September 2017

release_oloczgwm4jcrpmcvlmelnryq2a

1 reference

https://api.fatcat.wiki/v0/release/oloczgwm4jcrpmcvlmelnryq2a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39078274&oldid=1836243222"